Zacks Investment Research on MSN4h
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...
Verywell Health on MSN10mon
Evenity vs. Prolia: Which Is Better for Osteoporosis?
Osteoporosis is a common bone disease characterized by the progressive loss of bone mass and bone density. Osteoporosis ...
pharmaphorum5y
At long last, Amgen/UCB score FDA okay for Evenity
Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...
pharmaphorum5y
CHMP says no to Amgen’s osteoporosis drug Evenity
Amgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody therapy for osteoporosis. The EMA’s Committee for Medicinal Products for Human Use (CHMP ...
Mena FN12d
Global Evenity Market: Key Trends, Market Share, Growth Drivers, And Forecast
Is the Evenity Market Set to Witness Substantial Growth? The Evenity market has experienced steady expansion in recent years, demonstrating a strong historical compound annual growth rate (HCAGR ...
Insider Monkey21d
10 Best Retirement Stocks to Buy According to Hedge Funds
Repatha and EVENITY are two medications that are producing significant growth for the company. On February 20, Bernstein analysts reduced the price target for Amgen (NASDAQ:AMGN) shares to $350 ...
The Victoria Advocate19d
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
BIMZELX ®, EVENITY ®, FINTEPLA ®, RYSTIGGO ® and ZILBRYSQ ® as well as solid contribution from CIMZIA ® and BRIVIACT ® reaching its peak sales two years ahead of target Underlying ...